Cladribina (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Cladribina" in Italian language version.

refsWebsite

Global rank Italian rank

4^th place

9^th place

2^nd place

7^th place

5clinicaltrials.gov

5,225^th place

5,296^th place

3web.archive.org

1^st place

1^st place

799^th place

22^nd place

2oxfordjournals.org

1,389^th place

732^nd place

2bloodjournal.org

low place

low place

low place

low place

1hematology.org

low place

low place

49^th place

129^th place

1,071^st place

9,950^th place

719^th place

799^th place

1genengnews.com

low place

low place

1notiziariochimicofarmaceutico.it

low place

low place

low place

7,927^th place

68^th place

57^th place

1mantlecelllymphoma.org

low place

low place

aism.it

La Commissione Europea approva l'immissione in commercio di cladribina (Mavenclad®) - Associazione Italiana Sclerosi Multipla, su aism.it. URL consultato il 31 gennaio 2018.

bloodjournal.org

Robak T, Jamroziak K, Gora-Tybor J, et al., Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial ^{[collegamento interrotto]}, in Blood, vol. 109, n. 9, 2007, pp. 3672–5, DOI:10.1182/blood-2006-08-042929, PMID 17209059.
Saven A, Burian C, Adusumalli J, Koziol JA, Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia ^{[collegamento interrotto]}, in Blood, vol. 93, n. 8, 1999, pp. 2471–7, PMID 10194424.

clinicaltrials.gov

(EN) A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) - Full Text View - ClinicalTrials.gov. URL consultato il 31 gennaio 2018.
(EN) CLARITY Extension Study - Full Text View - ClinicalTrials.gov. URL consultato il 31 gennaio 2018.
(EN) Oral Cladribine in Early Multiple Sclerosis (MS) - Full Text View - ClinicalTrials.gov. URL consultato il 31 gennaio 2018.
(EN) A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD) - Full Text View - ClinicalTrials.gov. URL consultato il 31 gennaio 2018.
(EN) Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials - Full Text View - ClinicalTrials.gov. URL consultato il 31 gennaio 2018.

doi.org

dx.doi.org

Else M, Dearden CE, Matutes E, et al., Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis, in Br. J. Haematol., vol. 145, n. 6, marzo 2009, pp. 733–40, DOI:10.1111/j.1365-2141.2009.07668.x, PMID 19344416.
G. Juliusson, H. Samuelsson, Hairy cell leukemia: epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous therapy., in Leuk Lymphoma, 52 Suppl 2, giugno 2011, pp. 46-9, DOI:10.3109/10428194.2011.565842, PMID 21599605.
von Rohr A, Schmitz SF, Tichelli A, et al., Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study, in Ann. Oncol., vol. 13, n. 10, 2002, pp. 1641–9, DOI:10.1093/annonc/mdf272, PMID 12377655.
Robak T, Jamroziak K, Gora-Tybor J, et al., Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial ^{[collegamento interrotto]}, in Blood, vol. 109, n. 9, 2007, pp. 3672–5, DOI:10.1182/blood-2006-08-042929, PMID 17209059.
Van Den Neste E, Delannoy A, Vandercam B, et al., Infectious complications after 2-chlorodeoxyadenosine therapy, in Eur. J. Haematol., vol. 56, n. 4, 1996, pp. 235–40, DOI:10.1111/j.1600-0609.1996.tb01935.x, PMID 8641392.
Lauria F, Benfenati D, Raspadori D, Rondelli D, Zinzani PL, Tura S, High complete remission rate in hairy cell leukemia treated with 2-chlorodeoxyadenosine, in Leuk. Lymphoma, vol. 11, 5–6, 1993, pp. 399–404, DOI:10.3109/10428199309067932, PMID 7907247.

europa.eu

ec.europa.eu

(EN) Public Health - European Commission (PDF), su Public Health. URL consultato il 31 gennaio 2018.

genengnews.com

News Highlights: Merck Serono Gives Up on Getting Drug Candidate for Multiple Sclerosis Approved

hematology.org

Lichtman, Marshall A., Josef Prchal, and Karl Blume, Wallace H. Coulter Award for Lifetime Achievement in Hematology: Inaugural Award Winner Ernest Beutler, MD, in The Hematologist, American Society of Hematology, 1º gennaio 2008.

mantlecelllymphoma.org

Mantle Cell Lymphoma initiative Archiviato il 6 ottobre 2007 in Internet Archive.

medscape.com

Medscape

n-tv.de

EU-Bedenken gegen Cladribin: Merck erleidet herben Schlag

nih.gov

ncbi.nlm.nih.gov

(EN) Giovannoni, et al., A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis., in N Engl J Med, vol. 362, n. 5, 2010, pp. 416-26.
Else M, Dearden CE, Matutes E, et al., Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis, in Br. J. Haematol., vol. 145, n. 6, marzo 2009, pp. 733–40, DOI:10.1111/j.1365-2141.2009.07668.x, PMID 19344416.
G. Juliusson, H. Samuelsson, Hairy cell leukemia: epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous therapy., in Leuk Lymphoma, 52 Suppl 2, giugno 2011, pp. 46-9, DOI:10.3109/10428194.2011.565842, PMID 21599605.
von Rohr A, Schmitz SF, Tichelli A, et al., Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study, in Ann. Oncol., vol. 13, n. 10, 2002, pp. 1641–9, DOI:10.1093/annonc/mdf272, PMID 12377655.
(HR) Aurer I, Mitrović Z, Kovacević-Metelko J, et al., [Treatment of hairy cell leukemia with cladribine], in Lijec Vjesn, vol. 129, 3–4, 2007, pp. 80–3, PMID 17557550.
Robak T, Jamroziak K, Gora-Tybor J, et al., Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial ^{[collegamento interrotto]}, in Blood, vol. 109, n. 9, 2007, pp. 3672–5, DOI:10.1182/blood-2006-08-042929, PMID 17209059.
Van Den Neste E, Delannoy A, Vandercam B, et al., Infectious complications after 2-chlorodeoxyadenosine therapy, in Eur. J. Haematol., vol. 56, n. 4, 1996, pp. 235–40, DOI:10.1111/j.1600-0609.1996.tb01935.x, PMID 8641392.
Saven A, Burian C, Adusumalli J, Koziol JA, Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia ^{[collegamento interrotto]}, in Blood, vol. 93, n. 8, 1999, pp. 2471–7, PMID 10194424.
Nelson MC, Hogan DK, The role of cladribine in the treatment of lymphoid malignancies, in Oncol Nurs Forum, vol. 22, n. 9, 1995, pp. 1395–400, PMID 8539180.
Lauria F, Benfenati D, Raspadori D, et al., Retreatment with 2-CdA of progressed HCL patients, in Leuk. Lymphoma, 14 Suppl 1, 1994, pp. 143–5, PMID 7820047.
Lauria F, Benfenati D, Raspadori D, Rondelli D, Zinzani PL, Tura S, High complete remission rate in hairy cell leukemia treated with 2-chlorodeoxyadenosine, in Leuk. Lymphoma, vol. 11, 5–6, 1993, pp. 399–404, DOI:10.3109/10428199309067932, PMID 7907247.
Juliusson G, Lenkei R, Tjønnfjord G, Heldal D, Liliemark J, Neutropenic fever following cladribine therapy for symptomatic hairy-cell leukemia: predictive factors and effects of granulocyte-macrophage colony-stimulating factor, in Ann. Oncol., vol. 6, n. 4, aprile 1995, pp. 371–5, PMID 7619752.

notiziariochimicofarmaceutico.it

Profilo beneficio/rischio positivo di cladribina per la SM recidivante • NCF, in NCF - Notiziario Chimico Farmaceutico, 5 novembre 2017. URL consultato il 31 gennaio 2018.

oadoi.org

Else M, Dearden CE, Matutes E, et al., Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis, in Br. J. Haematol., vol. 145, n. 6, marzo 2009, pp. 733–40, DOI:10.1111/j.1365-2141.2009.07668.x, PMID 19344416.
Van Den Neste E, Delannoy A, Vandercam B, et al., Infectious complications after 2-chlorodeoxyadenosine therapy, in Eur. J. Haematol., vol. 56, n. 4, 1996, pp. 235–40, DOI:10.1111/j.1600-0609.1996.tb01935.x, PMID 8641392.
Lauria F, Benfenati D, Raspadori D, Rondelli D, Zinzani PL, Tura S, High complete remission rate in hairy cell leukemia treated with 2-chlorodeoxyadenosine, in Leuk. Lymphoma, vol. 11, 5–6, 1993, pp. 399–404, DOI:10.3109/10428199309067932, PMID 7907247.

oxfordjournals.org

annonc.oxfordjournals.org

von Rohr A, Schmitz SF, Tichelli A, et al., Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study, in Ann. Oncol., vol. 13, n. 10, 2002, pp. 1641–9, DOI:10.1093/annonc/mdf272, PMID 12377655.
Juliusson G, Lenkei R, Tjønnfjord G, Heldal D, Liliemark J, Neutropenic fever following cladribine therapy for symptomatic hairy-cell leukemia: predictive factors and effects of granulocyte-macrophage colony-stimulating factor, in Ann. Oncol., vol. 6, n. 4, aprile 1995, pp. 371–5, PMID 7619752.

pharmastar.it

(EN) MedicalStar, Sclerosi multipla, Merck ci riprova con cladribina, su pharmastar.it. URL consultato il 31 gennaio 2018.

reuters.com

Ben Hirschler, UPDATE 1-Russia okays Merck KGaA's multiple sclerosis pill, in Reuters, 12 luglio 2010.

web.archive.org

"Oral Multiple Sclerosis Therapies Spark Excitement, Concern" Internal Medicine News, April, 2011. Copia archiviata, su internalmedicinenews.com. URL consultato il 31 gennaio 2012 (archiviato dall'url originale il 28 marzo 2012).
Mantle Cell Lymphoma initiative Archiviato il 6 ottobre 2007 in Internet Archive.
Leustatin prescribing information (PDF), su orthobiotech.com, Ortho Biotech Products, L.P. (a subsidiary of Johnson & Johnson, agosto 2007 revision. URL consultato il 31 gennaio 2012 (archiviato dall'url originale il 12 novembre 2008).